How placental growth factor detection might improve diagnosis and management of pre-eclampsia

Expert Review of Molecular Diagnostics

Volumn 14, Issue 4, 2014, Pages 403-406

  Duhig, Kate E ^a   Chappell, Lucy C ^a   Shennan, Andrew H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

angiogenesis; diagnosis; placental growth factor; pre eclampsia; pregnancy

Indexed keywords

JANUS KINASE 1; MAGNESIUM SULFATE; PLACENTAL GROWTH FACTOR; PLACENTA PROTEIN;

BLOOD VESSEL REACTIVITY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FETUS DEATH; FETUS DISEASE; FETUS GROWTH; HUMAN; MATERNAL DISEASE; MATERNAL MORTALITY; NEUROPROTECTION; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PROTEINURIA; REVIEW; ANIMAL; FEMALE; METABOLISM; PRE-ECLAMPSIA;

ANIMALS; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS;

EID: 84898946170     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.908121     Document Type: Review

References (28)

1. World Health Organization. The World Health report 2005: make every mother and child count. Available from: www.who.int/whr/2005/whr2005-en.pdf
2. National Institute for Health and Clinical Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. Available from: www. nice.org.uk/nicemedia/live/13098/50418/50418.pdf
3. Lowe SA, Brown MA, Dekker GA, et al. Guidelines for the management of hypertensive disorders of pregnancy. 2008; Aust N Z J Obstet Gynaecol 2009;49:242-6
4. Douglas K, Redman C. Eclampsia in the United Kingdom. BMJ 1994;309(6966): 1395-400 (Pubitemid 24351401
5. Poulton L, Halligan A, Shennan AH. Lack of consistency in research papers over the definition of pre-eclampsia. Br J Obstet Gynaecol 1999;106(9):983-5 (Pubitemid 29415633
6. Villar J, Say L, Shennan et al. Methodological and technical issues related to the diagnosis, screening, prevention, and treatment of pre-eclampsia and eclampsia. Int J Obstet Gynaecol 2004;85(Suppl 1): S28-41
7. Durnwald C, Mercer B. A prospective comparison of total protein/creatinine ratio versus 24-hour urine protein in women with suspected preeclampsia. Am J Obstet Gynecol 2003;189:848-52 (Pubitemid 37194120
8. Waugh J, Bell SC, Kilby MD, et al. Urine protein estimation in hypertensive pregnancy: which thresholds and laboratory assay best predict clinical outcome. Hypertens Pregnancy 2005;24(3):291-302 (Pubitemid 41579639
9. Morris RK, Riley RD, Doug M, et al. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ 2012;345:e4342
10. Altman D, Carroli G, Duley L, et al. Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359(9321):1877-90 (Pubitemid 34615765
11. Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009 (1):CD004661
12. Shore VH, Wang TH, Wang CL, et al. Vascular endothelial growth factor, placenta growth factor and their receptors inisolated human trophoblast. Placenta 1997;18: 657-65 (Pubitemid 27448423
13. Andraweera PH, Dekker GA, Roberts CT. The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update 2012;18(4):436-57
14. Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007;109(6):1316-24 (Pubitemid 46869870
15. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008;75(1):1-8 (Pubitemid 350266733
16. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011;108(4):1451-5
17. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350: 672-83 (Pubitemid 38364626
18. Anderson UD, Olsson MG, Kristensen KH, et al. Review: biochemical markers to predict preeclampsia. Placenta 2012;33: S42-7
19. Foidart JM, Schaaps JP, Chantraine F, et al. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer. J Reprod Immunol 2009; 82(2):106-11
20. Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007;109:168-80 (Pubitemid 46035522
21. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al. EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012; 19(7):778-87
22. Rana S, Karumanchi SA, Lindheimer MD. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension 2014;63(2):198-202
23. Chappell C, Duckworth S, Seed P, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicentre trial. Circulation 2013;128:2121-31
24. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125(7): 911-19
25. Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012;25(12):2651-7
26. Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31(3): 141-6
27. Myatt L, Clifton RG, Roberts JM, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG 2013;120(10): 1183-91
28. Myers JE, Kenny LC, McCowan LM, et al. SCOPE consortium. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 2013;120(10):1215-23